Tags : advance

Biotech

Merck Signs a Five-Year Agreement with M2GEN to Advance Cancer

Shots: The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented, de-identified clinical and genomic data to support Merck’s oncology efforts The data will be accessed through M2GEN’s ORIEN which is a network of 18 cancer centers across the US The collaboration provides utility […]Read More

Biotech

GSK Expand its 2020 Collaboration with Vir to Advance New

Shots: Vir will receive ~$225M up front, $120M as an equity investment and $200M as regulatory milestones, ~300M as option payment and will be responsible to fund the development of VIR-2482 through the completion of the P-II trial GSK to get an exclusive option to co-develop VIR-2482 after Vir completes and reports P-II trial outcomes, […]Read More

Clinical Trials

AbbVie Reports Results of Skyrizi (risankizumab) in P-III Induction Studies

Shots: The P-III ADVANCE & MOTIVATE studies involves assessing of Risankizumab (600/1200mg) vs PBO in adult patients with mod. to sev. CD who had an inadequate response/ were intolerant to conventional and/or biologic therapy & patients who had responded inadequately or were intolerant to biologic therapy respectively Results: @12wks. clinical remission as per CDAI (45%/42% […]Read More

Clinical Trials

Sanofi and Translate Bio to Advance MRT5500 into Clinical Study

Shots: The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of […]Read More